AU737613B2 - Use of chelerythrine and radiation for tumor therapy - Google Patents

Use of chelerythrine and radiation for tumor therapy Download PDF

Info

Publication number
AU737613B2
AU737613B2 AU68693/98A AU6869398A AU737613B2 AU 737613 B2 AU737613 B2 AU 737613B2 AU 68693/98 A AU68693/98 A AU 68693/98A AU 6869398 A AU6869398 A AU 6869398A AU 737613 B2 AU737613 B2 AU 737613B2
Authority
AU
Australia
Prior art keywords
chelerythrine
cell
ionizing radiation
tumor cell
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU68693/98A
Other languages
English (en)
Other versions
AU6869398A (en
Inventor
Steven J. Chmura
Donald W Kufe
Jose Quintans
Ralph R Weichselbaum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Chicago
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Arch Development Corp filed Critical Dana Farber Cancer Institute Inc
Publication of AU6869398A publication Critical patent/AU6869398A/en
Application granted granted Critical
Publication of AU737613B2 publication Critical patent/AU737613B2/en
Assigned to UNIVERSITY OF CHICAGO, THE, DANA-FARBER CANCER INSTITUTE reassignment UNIVERSITY OF CHICAGO, THE Alteration of Name(s) in Register under S187 Assignors: ARCH DEVELOPMENT CORPORATION, DANA-FARBER CANCER INSTITUTE
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU68693/98A 1997-03-25 1998-03-25 Use of chelerythrine and radiation for tumor therapy Ceased AU737613B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/826814 1997-03-25
US08/826,814 US6025365A (en) 1997-03-25 1997-03-25 Chelerythrine and radiation combined tumor therapy
PCT/US1998/005842 WO1998042339A1 (en) 1997-03-25 1998-03-25 Use of chelerythrine and radiation for tumor therapy

Publications (2)

Publication Number Publication Date
AU6869398A AU6869398A (en) 1998-10-20
AU737613B2 true AU737613B2 (en) 2001-08-23

Family

ID=25247609

Family Applications (1)

Application Number Title Priority Date Filing Date
AU68693/98A Ceased AU737613B2 (en) 1997-03-25 1998-03-25 Use of chelerythrine and radiation for tumor therapy

Country Status (12)

Country Link
US (1) US6025365A (enExample)
EP (1) EP0971710B1 (enExample)
JP (1) JP2001521552A (enExample)
CN (1) CN1172668C (enExample)
AT (1) ATE267599T1 (enExample)
AU (1) AU737613B2 (enExample)
CA (1) CA2284992A1 (enExample)
DE (1) DE69824165T2 (enExample)
DK (1) DK0971710T3 (enExample)
ES (1) ES2218814T3 (enExample)
PT (1) PT971710E (enExample)
WO (1) WO1998042339A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426351B1 (en) * 2000-08-11 2002-07-30 Dana-Farber Cancer, Inc. Chelerythrine-based therapies for cancer
WO2003005965A2 (en) * 2001-07-11 2003-01-23 Musc Foundation For Research Development Modulators of ceramidase and methods of use based thereon
US20030028097A1 (en) * 2001-08-03 2003-02-06 D'amico Anthony V. Immobilizer probe system and method
WO2004016211A2 (en) * 2002-08-08 2004-02-26 Vanderbilt University Pi3k antagonists as radiosensitizers
JP2004284961A (ja) * 2003-03-19 2004-10-14 Okinawa Pref Gov 抗腫瘍成分をサルカケミカンから抽出した製剤、食品または食品添加物
CN1292750C (zh) * 2003-06-02 2007-01-03 张平 植物来源总生物碱组合物及其药物制剂
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
KR100822887B1 (ko) 2006-10-12 2008-04-17 한국생명공학연구원 치매의 치료 또는 예방을 위한 조성물
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
CN101904849A (zh) * 2010-08-19 2010-12-08 苏州大学 血根碱制备肿瘤放射治疗增敏药物的应用
CN102552264A (zh) * 2012-02-28 2012-07-11 苏州大学 血根碱在制备电离辐射防护剂中的应用
CN116407537A (zh) * 2023-03-03 2023-07-11 长春中医药大学 一种白屈菜红碱在制备用于治疗卵巢癌的药物中的用途
CN118304300B (zh) * 2024-04-12 2025-03-14 儋州市人民医院 一种具有麻醉作用的组合物及其在制备麻醉药物中的应用
CN119548502A (zh) * 2024-11-19 2025-03-04 中国药科大学 白屈菜红碱在制备黑色素瘤治疗药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004761A1 (en) * 1995-07-28 1997-02-13 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US209331A (en) * 1878-10-29 Improvement in medical compounds
US433257A (en) * 1890-07-29 Salve
US2344830A (en) * 1940-08-15 1944-03-21 Wisconsin Alumni Res Found Composition of matter for the chemical fixation of diseased tissue preparatory for surgical removal
US4145412A (en) * 1977-02-14 1979-03-20 Vipont Chemical Company Composition for application to oral cavity and method for preparation thereof
US4406881A (en) * 1980-05-20 1983-09-27 Vipont Laboratories Antimicrobial agent
US4376115A (en) * 1980-08-05 1983-03-08 Mccrorey Howard S Method and composition for treating teeth and method for preparing same
US4599228A (en) * 1981-01-19 1986-07-08 Vipont Laboratories, Inc. Antimicrobial agent
US5324520A (en) * 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
HUP9601096A2 (hu) * 1996-04-26 1998-01-28 János Aradi Anti-HIV-aktivitással rendelkező gyógynövényalapú gyógyászati és gyógyhatású készítmény,és vegyületek

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997004761A1 (en) * 1995-07-28 1997-02-13 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders

Also Published As

Publication number Publication date
CA2284992A1 (en) 1998-10-01
PT971710E (pt) 2004-09-30
CN1172668C (zh) 2004-10-27
CN1255061A (zh) 2000-05-31
ES2218814T3 (es) 2004-11-16
DK0971710T3 (da) 2004-09-27
ATE267599T1 (de) 2004-06-15
US6025365A (en) 2000-02-15
JP2001521552A (ja) 2001-11-06
WO1998042339A1 (en) 1998-10-01
DE69824165T2 (de) 2005-06-09
EP0971710A1 (en) 2000-01-19
DE69824165D1 (de) 2004-07-01
AU6869398A (en) 1998-10-20
EP0971710B1 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
AU737613B2 (en) Use of chelerythrine and radiation for tumor therapy
JP7671327B2 (ja) 消化管間質腫瘍の治療のための併用療法
US6319931B1 (en) Use of a compound with affinity for the mitochondrial benzodiazepine receptor in cancer therapy
Khan et al. Head and neck cancer radiosensitization by the novel poly (ADP‐ribose) polymerase inhibitor GPI‐15427
US6214821B1 (en) Methods and composition for the inhibition of cancer cells
SK154796A3 (en) Use of rapamycin for the inhibition of neuronal cells necrosis
WO2010082813A1 (en) Method of treating cancer
JP2017519019A (ja) ｍｄｍ２阻害剤の間欠投与
US20220211690A1 (en) Methods for treating pten-mutant tumors
US6426351B1 (en) Chelerythrine-based therapies for cancer
WO1997027848A1 (en) SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS
WO1997027848A9 (en) SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS
KR20220130190A (ko) 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제
US20040191168A1 (en) Tumor cell killing by cell cycle checkpoint abrogation combined with Inhibition of the classical mitogen activated protein (map) kinase pathway
Pauwels et al. Unraveling the mechanism of radiosensitization by gemcitabine: the role of TP53
Schenone et al. New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms
US20010051628A1 (en) Methods to modulate the resistance of cells to apoptosis mediated by mutant epidermal growth factor receptors
TWI501762B (zh) 阿達帕林治療癌症的新穎用途
Tenzer et al. Signal transduction inhibitors as radiosensitizers
AU2007200097A1 (en) Chelerythrine-based therapies for cancer
CA3089566C (en) Combination therapy for the treatment of gastrointestinal stromal tumors
US20030207933A1 (en) Compositions and methods for increasing the sensitivity of apoptosis-resistant tumor cells to inducers of apoptosis
KR20220140723A (ko) 암의 치료를 위한 약제학적 조합
Grinshtein et al. Small Molecule Kinase Inhibitor Screen Identifies Polo-Like
Byrd et al. B family of proteins to induce apoptosis in CLL: κ 17-DMAG targets the NF

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)